Evidence map›Paper›PMID 19804638›Full record

ArticleGenome biology2009

MethMarker: user-friendly design and optimization of gene-specific DNA methylation assays.

Peter Schüffler, Thomas Mikeska, Andreas Waha, Thomas Lengauer, Christoph Bock

Open access · hybridAbstract read
In one paragraph

Article in Genome biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Analysing and interpreting DNA methylation data.Nature reviews. Genetics · 2012
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Peter SchüfflerMax-Planck-Institut für Informatik, Saarbrücken, Germany. schueffi@mpi-inf.mpg.de
Thomas Mikeska
Andreas Waha
Thomas Lengauer
Christoph Bock
Max Planck Institute for Informatics · DEMax Planck Society · DEPeter MacCallum Cancer Centre · AUUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA methylation is a key mechanism of epigenetic regulation that is frequently altered in diseases such as cancer. To confirm the biological or clinical relevance of such changes, gene-specific DNA methylation changes need to be validated in multiple samples. We have developed the MethMarker http://methmarker.mpi-inf.mpg.de/ software to help design robust and cost-efficient DNA methylation assays for six widely used methods. Furthermore, MethMarker implements a bioinformatic workflow for transforming disease-specific differentially methylated genomic regions into robust clinical biomarkers.

Indexed as

SoftwareSoftware DesignBiological AssayBiomarkersDNA MethylationDNA Modification MethylasesDNA Repair EnzymesHumansReproducibility of ResultsSequence Analysis, DNATumor Suppressor ProteinsBiomarkersDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanTumor Suppressor Proteins

Identifiers

PMID19804638
PMCPMC2784320
OpenAlexW2138491564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.